SAFC appointed by BTG for development services

Published: 10-Oct-2006

SAFC, a member of the Sigma-Aldrich Group, has announced that its SAFC Pharma business segment, will provide chemical development services relating to BGC20-1259, a potential treatment for Alzheimer's disease, to BTG, the medical innovations company.


SAFC, a member of the Sigma-Aldrich Group, has announced that its SAFC Pharma business segment, will provide chemical development services relating to BGC20-1259, a potential treatment for Alzheimer's disease, to BTG, the medical innovations company.

BGC20-1259, currently in Phase I clinical studies, is a unique, multi-functional compound being developed to target the cognitive impairment and behavioural aspects of Alzheimer's disease, as well as provide neuroprotection against the disease.

SAFC Pharma chemists at the Manchester UK facility will conduct process research and development studies on the synthesis of BGC20-1259 to determine a suitable process for the manufacture of sufficient quantities of material to be included in clinical trials. Following process development, cGMP manufacturing of the compound is anticipated.

"The SAFC Pharma team impressed us with their abilities and experience in small molecule chemical development and cGMP manufacturing. We are very pleased that they will be assisting BTG with this section of the BGC20-1259 program,. said Carol Routledge, Head of Clinical Development at BTG.

  • Companies:
  • Merck Group
See more

You may also like

Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Read more
Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Research & Development

Quibim partners with Merck KGaA to develop imaging-based diagnostics

Quibim and Merck KGaA have partnered to develop diagnostic tools which will fortify the implementation of personalised medicine
Sustainability

Altenex Energy advises Merck KGaA on power purchase agreement for 130 MW of new wind and solar in Spain

Deal advances Merck KGaA, Darmstadt, Germany’s climate commitments and will deliver needed renewable energy to the region
Manufacturing

MilliporeSigma invests $25m into cell culture media

The subsidiary of Merck has announced the expansion of its facility in Lenexa, Kansas, adding 98,000 sqft of lab space in the process
Manufacturing

Improving the operational efficiency of single-use assemblies in liquid bioprocessing

Merck recently announced the launch of its Ultimus Single-Use Process Container Film, which has been designed to provide extreme durability and leak resistance for the single-use assemblies used during bioprocessing liquid applications. Dr Kevin Robinson spoke to Greg Verni, Head of Single-Use and Systems, to find out more
Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers
Drug Delivery

Merck invests €290m in biosafety testing capacity

The company aims to increase its Group sales to approximately €25 billion by 2025
Subscribe now